BIOVENTUS INC. - CLASS A COMMON STOCK

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

08 авг 2023 06:30:01 Источник Nasdaq GlobeNewswire

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

04 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

01 авг 2023 16:35:30 Источник Nasdaq GlobeNewswire

Bioventus Completes Divestiture of its Wound Business

23 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Bioventus Reports First Quarter Financial Results

16 май 2023 15:15:00 Источник Nasdaq GlobeNewswire

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

15 май 2023 16:33:04 Источник Nasdaq GlobeNewswire

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

11 май 2023 06:00:02 Источник Nasdaq GlobeNewswire

Bioventus Announces Divestiture of its Wound Business

10 май 2023 08:00:00 Источник Nasdaq GlobeNewswire

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

03 май 2023 07:30:00 Источник Nasdaq GlobeNewswire

Bioventus Announces CEO Leadership Change

05 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire

Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

31 мар 2023 06:30:01 Источник Nasdaq GlobeNewswire

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

31 мар 2023 06:00:00 Источник Nasdaq GlobeNewswire

Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023

29 мар 2023 07:55:09 Источник Nasdaq GlobeNewswire

Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023

16 мар 2023 07:30:00 Источник Nasdaq GlobeNewswire

Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition

28 фев 2023 06:30:00 Источник Nasdaq GlobeNewswire

Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire

Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance

21 ноя 2022 16:15:01 Источник Nasdaq GlobeNewswire

Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022

16 ноя 2022 16:15:00 Источник Nasdaq GlobeNewswire

Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance

08 ноя 2022 06:30:01 Источник Nasdaq GlobeNewswire

Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022

31 окт 2022 06:00:00 Источник Nasdaq GlobeNewswire